Novo Nordisk is undergoing a leadership transition with Maziar Mike Doustdar set to assume CEO duties amid intensifying competition in the GLP-1 obesity and diabetes drug market. Sales growth has slowed as rivals Eli Lilly gains ground with newer competitors and compounding businesses challenge market share. The company recently discontinued several pipeline programs, including FGF21 analogs, following clinical failures, sparking speculation about a strategic refocus under new management. Despite rising sales of core products like Ozempic and Wegovy, Novo's share price has dropped significantly, reflecting market concerns over growth prospects and competitive pressures.